Pernille G Thrane1, Steen D Kristensen1, Kevin K W Olesen1, Leif S Mortensen2, Hans Erik Bøtker1, Leif Thuesen3, Henrik S Hansen4, Ulrik Abildgaard5, Thomas Engstrøm6, Henning R Andersen1, Michael Maeng1. 1. Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark. 2. Spange Statistics, Elleparken 10, 8520 Lisbjerg, Denmark. 3. Department of Cardiology, Hobrovej 18-20, 9000 Aalborg University Hospital, Aalborg, Denmark. 4. Department of Cardiology, Odense University Hospital, J. B. Winsløws Vej 4, 5000 Odense C, Denmark. 5. Department of Cardiology, Copenhagen University Hospital Gentofte, Gentofte Hospitalsvej 1, 2900 Hellerup, Denmark. 6. Department of Cardiology, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen Ø, Denmark.
Abstract
AIMS: The DANish Acute Myocardial Infarction 2 (DANAMI-2) trial found that interhospital transport to primary percutaneous coronary intervention (pPCI) was superior to fibrinolysis at the local hospital in patients with ST-segment elevation myocardial infarction (STEMI) at 30 days. The present study investigates the 16-year cardiovascular outcomes. METHODS AND RESULTS: We randomized 1572 STEMI patients to pPCI or fibrinolysis at 24 referral hospitals and 5 invasive centres in Denmark. Patients randomized to pPCI at referral hospitals were immediately transported to the nearest invasive centre. The main endpoint of the current study was a composite of death or rehospitalization for myocardial infarction (MI). Outcome information beyond 3 years was obtained through Danish health registries. After 16 years, pPCI-treated patients had a sustained lower rate of composite endpoint compared to patients treated with fibrinolysis in the overall cohort [58.7% vs. 62.3%; hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76-0.98], and among patients transported for pPCI (58.7% vs. 64.1%; HR 0.82, 95% CI 0.71-0.96). No difference in all-cause mortality was found, but cardiac mortality was reduced by an absolute of 4.4% in favour of pPCI (18.3% vs. 22.7%; HR 0.78, 95% CI 0.63-0.98). pPCI postponed a main event with 12.3 months in average compared to fibrinolysis (95% CI 5.0-19.5). CONCLUSION: The benefit of pPCI over fibrinolysis was maintained at 16-year follow-up. pPCI reduced the composite endpoint of death or rehospitalization for MI, reduced cardiac mortality, and delayed average time to a main event by approximately 1 year. Published on behalf of the European Society of Cardiology. All rights reserved.
RCT Entities:
AIMS: The DANish Acute Myocardial Infarction 2 (DANAMI-2) trial found that interhospital transport to primary percutaneous coronary intervention (pPCI) was superior to fibrinolysis at the local hospital in patients with ST-segment elevation myocardial infarction (STEMI) at 30 days. The present study investigates the 16-year cardiovascular outcomes. METHODS AND RESULTS: We randomized 1572 STEMI patients to pPCI or fibrinolysis at 24 referral hospitals and 5 invasive centres in Denmark. Patients randomized to pPCI at referral hospitals were immediately transported to the nearest invasive centre. The main endpoint of the current study was a composite of death or rehospitalization for myocardial infarction (MI). Outcome information beyond 3 years was obtained through Danish health registries. After 16 years, pPCI-treated patients had a sustained lower rate of composite endpoint compared to patients treated with fibrinolysis in the overall cohort [58.7% vs. 62.3%; hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76-0.98], and among patients transported for pPCI (58.7% vs. 64.1%; HR 0.82, 95% CI 0.71-0.96). No difference in all-cause mortality was found, but cardiac mortality was reduced by an absolute of 4.4% in favour of pPCI (18.3% vs. 22.7%; HR 0.78, 95% CI 0.63-0.98). pPCI postponed a main event with 12.3 months in average compared to fibrinolysis (95% CI 5.0-19.5). CONCLUSION: The benefit of pPCI over fibrinolysis was maintained at 16-year follow-up. pPCI reduced the composite endpoint of death or rehospitalization for MI, reduced cardiac mortality, and delayed average time to a main event by approximately 1 year. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: M-J de Boer; J P Ottervanger; A W J Van't Hof; J C A Hoorntje; H Suryapranata; F Zijlstra Journal: Neth Heart J Date: 2022-09-16 Impact factor: 2.854
Authors: Isabel Galeano-Otero; Raquel Del Toro; Agustín Guisado; Ignacio Díaz; Isabel Mayoral-González; Francisco Guerrero-Márquez; Encarnación Gutiérrez-Carretero; Sara Casquero-Domínguez; Luis Díaz-de la Llera; Gonzalo Barón-Esquivias; Manuel Jiménez-Navarro; Tarik Smani; Antonio Ordóñez-Fernández Journal: J Clin Med Date: 2020-04-08 Impact factor: 4.241
Authors: Elias Haj-Yehia; Robert Werner Mertens; Florian Kahles; Marcia Viviane Rückbeil; Matthias Rau; Julia Moellmann; Moritz Biener; Mohammad Almalla; Jörg Schroeder; Evangelos Giannitsis; Hugo Albert Katus; Nikolaus Marx; Michael Lehrke Journal: J Clin Med Date: 2020-12-06 Impact factor: 4.241
Authors: Ricardas Radisauskas; Kawon Victoria Kim; Shannon Lange; Vaida Liutkute-Gumarov; Olga Mesceriakova-Veliuliene; Janina Petkeviciene; Mindaugas Stelemekas; Tadas Telksnys; Alexander Tran; Jürgen Rehm Journal: BMC Public Health Date: 2021-11-17 Impact factor: 3.295
Authors: Anne C Brøchner; Peter Lindholm; Margrethe J Jensen; Palle Toft; Finn L Henriksen; Jens F Lassen; Søren Mikkelsen Journal: Healthcare (Basel) Date: 2021-12-27